Methods for inhibiting HIV-1 infection
AssigneeProgenics Pharmaceuticals, Inc.
InventorsWilliam Olson, Paul Maddon
Life of this patent
Estimating the term…
Abstract
This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
Claims24
1-32. (canceled)
A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is reached an effective viral load-reducing amount of an IgG monoclonal antibody which (a) binds to a CCRS chemokine receptor, (b) inhibits binding of HIV-1JR-FL gp120/sCD4 complex to a CCR5 receptor on the surface of a CD4−CCR5+ cell, and (c) inhibits fusion of HIV-1 to a CD4+ CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's viral load prior to administration of any of the antibody to the subject, wherein the monoclonal antibody is PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or an antibody that cross-competes with monoclonal antibody PA14 for binding to the CCR5 receptor.
Dependencies are inferred from the claim text.